Lidocaine Inhibited Migration of NSCLCA549 Cells Via the CXCR4 Regulation

Overview

Journal Cancer Biomark

Publisher Sage Publications

Specialties Biochemistry
Oncology

Date 2021 Aug 2

PMID 34334384

Citations 4

Authors

Baichun Xing

Linlin Yang

Yanan Cui

Affiliations

Soon will be listed here.

Abstract

Background: Lidocaine is a local anesthetic that wildly used in surgical treatment and postoperative medical care for lung cancers. We hypothesized that lidocaine at clinical plasma concentration can inhibit CXCL12/CXCR4 axis-regulated cytoskeletal remodeling thereby reduce the migration of Non-small-cell lung cancers (NSCLC) cells.

Methods: We determined the effect of lidocaine at clinical plasma concentration on CXCL12-induced cell viability, apoptosis, cell death, monolayer cell wound healing rate, individual cell migration indicators, expression of CXCR4, CD44, and ICAM-1, intracellular Ca2+ level, and filamentous actin level alteration of NSCLC cells A549 and CXCR4-knocked down A549 cells using CCK-8, Bcl-2 ELISA, Cell death ELISA, wound healing assay, chemotaxis assay, western blotting, QPCR, Fura-2-based intracellular Ca2+ assay, and Fluorescein Phalloidin staining respectively.

Results: Lidocaine did not affect cell viability, apoptosis, and cell death but inhibited CXCL12-induced migration, intracellular Ca2+ releasing, and filamentous actin increase. Lidocaine decreased expression of CXCR4, increased CD44, but had no effect on ICAM-1. CXCL12 induced the increase of CD44 and ICAM-1 but did not affect CD44 in the presence of lidocaine. The knockdown of CXCR4 eliminated all the effects of lidocaine. The overexpression of CXCR4 promoted migration but the migration was inhibited by lidocaine.

Conclusion: Lidocaine at clinical plasma concentrations inhibited CXCL12-induced CXCR4 activation, thereby reduced the intracellular Ca2+-dependent cytoskeleton remodeling, resulting in slower migration of A549 cells.

Citing Articles

Chemokine CXCL12 Activates CXC Receptor 4 Metastasis Signaling Through the Upregulation of a CXCL12/CXCR4/MDMX (MDM4) Axis.

Lee R, Ellison V, Forbes D, Gao C, Katanov D, Kern A Cancers (Basel). 2025; 16(24.

PMID: 39766093 PMC: 11674518. DOI: 10.3390/cancers16244194.

The role of lidocaine in cancer progression and patient survival.

Chida K, Kanazawa H, Kinoshita H, Roy A, Hakamada K, Takabe K Pharmacol Ther. 2024; 259:108654.

PMID: 38701900 PMC: 11162934. DOI: 10.1016/j.pharmthera.2024.108654.

Trial watch: local anesthetics in cancer therapy.

Carnet Le Provost K, Kepp O, Kroemer G, Bezu L Oncoimmunology. 2024; 13(1):2308940.

PMID: 38504848 PMC: 10950281. DOI: 10.1080/2162402X.2024.2308940.

Lidocaine Inhibits Rat Prostate Cancer Cell Invasiveness and Voltage-Gated Sodium Channel Expression in Plasma Membrane.

Rizaner N, Fraser S, Gul I, Purut E, Djamgoz M, Altun S J Membr Biol. 2024; 257(1-2):17-24.

PMID: 38165418 DOI: 10.1007/s00232-023-00302-z.

miR-301a Deficiency Attenuates the Macrophage Migration and Phagocytosis through YY1/CXCR4 Pathway.

Xu J, Fu L, Deng J, Zhang J, Zou Y, Liao L Cells. 2022; 11(24).

PMID: 36552718 PMC: 9777533. DOI: 10.3390/cells11243952.

References

Chazotte B . Labeling cytoskeletal F-actin with rhodamine phalloidin or fluorescein phalloidin for imaging. Cold Spring Harb Protoc. 2010; 2010(5):pdb.prot4947. DOI: 10.1101/pdb.prot4947. View

Smith M, Luker K, Garbow J, Prior J, Jackson E, Piwnica-Worms D . CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004; 64(23):8604-12. DOI: 10.1158/0008-5472.CAN-04-1844. View

Piegeler T, Votta-Velis E, Liu G, Place A, Schwartz D, Beck-Schimmer B . Antimetastatic potential of amide-linked local anesthetics: inhibition of lung adenocarcinoma cell migration and inflammatory Src signaling independent of sodium channel blockade. Anesthesiology. 2012; 117(3):548-59. PMC: 3482823. DOI: 10.1097/ALN.0b013e3182661977. View

Chen Z, Fillmore C, Hammerman P, Kim C, Wong K . Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8):535-46. PMC: 5712844. DOI: 10.1038/nrc3775. View

Watanabe S, Imai K, Kimura T, Saito Y, Takashima S, Matsuzaki I . Effect of lidocaine cream analgesia for chest drain tube removal after video-assisted thoracoscopic surgery for lung cancer: a randomized clinical trial. Reg Anesth Pain Med. 2019; . DOI: 10.1136/rapm-2019-100760. View

Zhang Y, Zhan X, Xiong J, Peng S, Huang W, Joshi R . Temperature-dependent cell death patterns induced by functionalized gold nanoparticle photothermal therapy in melanoma cells. Sci Rep. 2018; 8(1):8720. PMC: 5992202. DOI: 10.1038/s41598-018-26978-1. View

Liu H, Xiong Y, Zhu X, Gao H, Yin S, Wang J . Icariin improves osteoporosis, inhibits the expression of PPARγ, C/EBPα, FABP4 mRNA, N1ICD and jagged1 proteins, and increases Notch2 mRNA in ovariectomized rats. Exp Ther Med. 2017; 13(4):1360-1368. PMC: 5377361. DOI: 10.3892/etm.2017.4128. View

Hoy H, Lynch T, Beck M . Surgical Treatment of Lung Cancer. Crit Care Nurs Clin North Am. 2019; 31(3):303-313. DOI: 10.1016/j.cnc.2019.05.002. View

He Z, Jia L, Lyu Y, Dong G, Jiang Y, Zheng J . [Increased expression of transendothelial migration-related molecules CCL4, ICAM-1 and VCAM-1 in lung tissue after surgical removal of mouse tumor-bearing lymph node]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020; 36(8):699-703. View

10.

Li R, Liu H, Dilger J, Lin J . Effect of Propofol on breast Cancer cell, the immune system, and patient outcome. BMC Anesthesiol. 2018; 18(1):77. PMC: 6020422. DOI: 10.1186/s12871-018-0543-3. View

11.

Oda T, Iwasa M, Aihara T, Maeda Y, Narita A . The nature of the globular- to fibrous-actin transition. Nature. 2009; 457(7228):441-5. DOI: 10.1038/nature07685. View

12.

Li X, Peng B, Zhu X, Wang P, Xiong Y, Liu H . Changes in related circular RNAs following ERβ knockdown and the relationship to rBMSC osteogenesis. Biochem Biophys Res Commun. 2017; 493(1):100-107. DOI: 10.1016/j.bbrc.2017.09.068. View

13.

Guo J, Chiu C, Wang M, Li F, Chen J . Proteoglycan serglycin promotes non-small cell lung cancer cell migration through the interaction of its glycosaminoglycans with CD44. J Biomed Sci. 2020; 27(1):2. PMC: 6939340. DOI: 10.1186/s12929-019-0600-3. View

14.

Wu Z, Ou L, Wang C, Yang L, Wang P, Liu H . Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation. Biomed Pharmacother. 2017; 94:1-9. DOI: 10.1016/j.biopha.2017.07.071. View

15.

Kotteas E, Boulas P, Gkiozos I, Tsagkouli S, Tsoukalas G, Syrigos K . The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis. Anticancer Res. 2014; 34(9):4665-72. View

16.

Wang H, Mo S, Yang L, Wang P, Sun K, Xiong Y . Effectiveness associated with different therapies for senile osteoporosis: a network Meta-analysis. J Tradit Chin Med. 2020; 40(1):17-27. View

17.

Zuo J, Wen M, Li S, Lv X, Wang L, Ai X . Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9. Oncol Lett. 2018; 14(6):7513-7521. PMC: 5755025. DOI: 10.3892/ol.2017.7168. View

18.

Zhou W, Guo S, Liu M, Burow M, Wang G . Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Curr Med Chem. 2017; 26(17):3026-3041. PMC: 5949083. DOI: 10.2174/0929867324666170830111531. View

19.

Phuchareon J, McCormick F, Eisele D, Tetsu O . EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A. 2015; 112(29):E3855-63. PMC: 4517222. DOI: 10.1073/pnas.1510733112. View

20.

Wang Z, Sun J, Feng Y, Tian X, Wang B, Zhou Y . Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. Tumour Biol. 2016; 37(7):8515-28. DOI: 10.1007/s13277-016-5016-z. View